Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease - PubMed
7 hours ago
- #Alzheimer's disease
- #Parkinson's disease
- #Biomarker
- Plasma P-tau217 is a sensitive biomarker for Alzheimer's disease (AD) co-pathology in Lewy body disorders (LBD).
- Higher plasma P-tau217 levels are associated with AD co-pathology in Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
- P-tau217 effectively discriminates LBD patients with AD co-pathology (AUC = 0.84).
- PD patients with cognitive decline show greater increases in serial P-tau217 levels compared to stable patients.
- Higher baseline P-tau217 predicts faster cognitive decline and higher risk of cognitive progression in PD.
- The study suggests P-tau217 could help identify LBD patients who may benefit from amyloid-targeting therapies.